Streetbeat News

Products Services

SNGX

Soligenix, Inc. announced the publication of a study demonstrating 100% protection by its bivalent vaccine against Sudan ebolavirus and Marburg virus in nonhuman primate models. The study, a collaboration with the University of Hawaiʻi at Mānoa, was published in the journal Vaccine and highlights the vaccine's preclinical efficacy and thermostability.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:31 pm

TSVT

JW Therapeutics has entered into an exclusive collaboration with 2seventy bio for the co-development and commercialization of a CAR-T therapy product for autoimmune diseases in Greater China. JW Therapeutics will handle process development and First-in-Human clinical trials in China, with costs shared by both parties. JW Therapeutics may also negotiate an exclusive license for the product in Greater China and is eligible to receive milestone payments and royalties from 2seventy bio.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:29 pm

MRNA

Moderna's CEO, in a letter to shareholders, announced the expected launch of an RSV vaccine candidate in 2024 and a combined Flu/Covid vaccine as early as 2025. The CEO anticipates sales growth for the company beginning in 2025 due to these new products.

Portfolio Pulse from Charles Gross

January 02, 2024 | 12:12 pm

VIRI

Virios Therapeutics has received guidance from the FDA on the requirements for progressing its IMC-2 treatment, a combination of Valacyclovir and Celecoxib, for symptoms associated with Long COVID illness, including fatigue and orthostatic intolerance.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:09 pm

PPTA

Perpetua Resources Corp. is progressing with the Stibnite Gold Project, aiming to supply the U.S. with antimony and establish a major gold mine. The company is advancing through the NEPA process and preparing for construction. Andrew Cole's appointment to the Board of Directors is expected to enhance operational expertise.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:07 pm

BRK

BYDDF

NIO

TSLA

XPEV

Wang Chuanfu, CEO of BYD Co., has been praised by Charlie Munger for his manufacturing prowess, surpassing Elon Musk in this regard. BYD, a Chinese EV maker, is challenging Tesla's market dominance with its range of affordable electric vehicles. Warren Buffett's Berkshire Hathaway invested in BYD in 2008, recognizing its potential. BYD's success is also due to competition with other Chinese EV makers like Nio Inc and Xpeng Inc. The company is expanding globally and is expected to launch third-generation EVs next year.

Portfolio Pulse from Ramakrishnan M

January 02, 2024 | 12:05 pm

NVS

VYGR

Voyager Therapeutics, Inc. (VYGR) has entered into a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NVS), to develop gene therapies for Huntington’s disease and spinal muscular atrophy. Voyager will grant Novartis access to its TRACER™ capsids and intellectual property for these diseases, and the two companies will work together on a preclinical gene therapy candidate for Huntington’s disease.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:02 pm

BMY

The European Medicines Agency (EMA) has validated Bristol Myers Squibb's application for repotrectinib, a treatment for locally advanced or metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors. This validation indicates that the application is complete and the EMA will now begin its formal review process. Repotrectinib is a targeted therapy designed to inhibit cancer growth in patients with specific genetic alterations, and its validation by the EMA is a crucial step towards potential approval and commercial availability in Europe.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:01 pm

BMY

Bristol Myers Squibb announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application for repotrectinib, a next-generation tyrosine kinase inhibitor. If approved, repotrectinib could become a leading treatment for ROS1-positive non-small cell lung cancer and NTRK-positive solid tumors in the EU.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:01 pm

VFS

VinFast, a global smart electric vehicle manufacturer, has signed agreements with five dealers in North Carolina, New York, Texas, and Kansas. These dealers will sell VinFast's electric vehicles, starting with the VF 8 SUV and later including the VF 6, VF 7, and VF 9 models as they become available in the US market.

Portfolio Pulse from Charles Gross

January 02, 2024 | 11:37 am